title: Evaluating a parainfluenza virus 5-based vaccine in a host with pre-existing immunity against parainfluenza virus 5.
abstract: Parainfluenza virus 5 (PIV5), formerly known as simian virus 5 (SV5), is a paramyxovirus often referred to as canine parainfluenza virus (CPI) in the veterinary field. PIV5 is thought to be a contributing factor to kennel cough. Kennel cough vaccines containing live PIV5 have been used in dogs for many decades. PIV5 is not known to cause any diseases in humans or other animals. PIV5 has been used as a vector for vaccine development for humans and animals. One critical question concerning the use of PIV5 as a vector is whether prior exposure to PIV5 would prevent the use of PIV5-based vaccines. In this work, we have examined immunogenicity of a recombinant PIV5 expressing hemagglutinin (HA) of influenza A virus subtype 3 (rPIV5-H3) in dogs that were immunized against PIV5. We found that vaccination of the dogs containing neutralizing antibodies against PIV5 with rPIV5-H3 generated immunity against influenza A virus, indicting that PIV5-based vaccine is immunogenic in dogs with prior exposure. Furthermore, we have examined exposure of PIV5 in human populations. We have detected neutralizing antibody (nAb) against PIV5 in 13 out of 45 human serum samples (about 29 percent). The nAb titers in humans were lower than that in vaccinated dogs, suggesting that nAb in humans is unlikely to prevent PIV5 from being an efficacious vector in humans.
authors.affiliation: Department of Infectious Diseases, University of Georgia College of Veterinary Medicine, Athens, Georgia, United States of America.
authors.forename: Zhenhai
authors.initials: Z
authors.lastname: Chen
authors.forename: Pei
authors.initials: P
authors.lastname: Xu
authors.forename: Gregory W
authors.initials: GW
authors.lastname: Salyards
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Harvey
authors.forename: Balazs
authors.initials: B
authors.lastname: Rada
authors.forename: Zhen F
authors.initials: ZF
authors.lastname: Fu
authors.forename: Biao
authors.initials: B
authors.lastname: He
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral / Q000097:blood*; D002460:Cell Line; D004283:Dog Diseases / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D004285:Dogs; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000235:genetics / Q000276:immunology; D006801:Humans; D007117:Immunization, Secondary; D009980:Influenza A virus / Q000737:chemistry; D045402:Parainfluenza Virus 5 / Q000187:drug effects / Q000276:immunology*; D019351:Rubulavirus Infections / Q000276:immunology / Q000517:prevention & control* / Q000662:veterinary* / Q000821:virology; D014611:Vaccination; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D014765:Viral Vaccines; C483468:hemagglutinin, human influenza A virus